SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and tests of key support levels dominate discussion, with many traders fearing further downside while others argue the market is oversold and see a potential bottom. Traders also point to ETF outflows, macroeconomic pressure, and exchange-security concerns as possible headwinds, but no single explanation is clearly established.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline alongside a broader crypto-market selloff has put the psychologically important $1 level in focus, with traders watching for a break and citing weak risk appetite and leveraged liquidations. The community is split between expecting further losses and treating the dip as an opportunity to accumulate.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the FDAs PDUFA decision on ivonescimab for EGFR-mutated lung cancer, with traders treating the outcome as a high-stakes binary event. The debate centers on the drugs strong progression-free-survival results and favorable but not statistically significant overall-survival data versus the FDAs stated need for significant survival evidence, leaving approval, a delay, or a rejection in question.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immixs NXC-201 CAR-T results in relapsed/refractory AL amyloidosis, including new ASH presentation data, are driving attention, with bullish traders emphasizing responses and safety as support for a future BLA. The optimism is tempered by concerns over financing dilution, a longer regulatory timeline, and weak biotech sentiment, while traders also debate short interest and the stocks decline.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention for a sharp, volatile pullback after a major prior rally, amid broader crypto weakness and reports of leveraged liquidations. Traders are split between calling the decline an oversold buying opportunity and expecting further losses, with many questioning whether ZEC can regain support.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 9.8476659 USD and is down -2.55 over the last 24 hours. It is currently trading on 2316 active market(s) with $307,298,586.51 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINK is drawing attention amid a volatile rally and renewed breakout talk, with traders citing Chainlinks role in tokenized-stock infrastructure and institutional adoption as bullish drivers. Others argue that partnerships and usage have not translated into lasting token gains, pointing to pullbacks and weak performance.

Pinterest, Inc. engages in the operation of an AI-powered visual search and discovery platform. It enables users to find inspiration, curate ideas, search for products, and discover content through visual recommendations. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is under pressure after Q3 results missed revenue expectations and its softer Q4 outlook prompted analyst target cuts, despite record user growth. Traders debate whether its growing audience and AI-powered shopping and ad products can drive stronger monetization, while skeptics question ad pricing and whether browsing converts to purchases.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP ETF inflows, regulatory-clarity speculation and institutional-adoption hopes are driving discussion around the Bitwise fund, alongside sharp swings in XRP and broader crypto markets. Bulls view the flows and potential policy progress as supportive, while skeptics question whether those developments will translate into sustained gains and point to recent weakness.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMAs stronger-than-expected Q3 results, led by accelerating ASCENIV growth and a higher earnings outlook, drove a sharp share-price rebound and renewed bullish discussion. Traders are debating whether the growth can sustain a broader rerating, while some point to lingering skepticism and weak follow-through; buyout talk remains speculation.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,704,555,155.77490568 with 589,238,111,425,239.3151592 in circulation. The last known price of Shiba Inu is 0.00000425 USD and is down -2.37 over the last 24 hours. It is currently trading on 1128 active market(s) with $56,784,935.49 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention amid a prolonged, choppy decline, with repeated chart commentary describing bearish structure and consolidation. Holders are split between hoping for a meme-coin rebound and expressing frustration over weak performance, limited utility, and stalled token burns.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seer Q3 2026 Earnings Call Transcript

Seer (NASDAQ:SEER) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...

Radoff-JEC Group Issues Open Letter Condemning Seers Unexplained and Seemingly Illogical Decision to Remain a Public Company

Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (Seer or the Company), today issued the following open letter. *** November 2, 2026 Fellow Stockholders and Members of the Board of Directors (the Board), On October...

Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.s Board of Directors

Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to director Meeta Gulyani. *** September 4, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn...

Radoff-JEC Group Calls on Seer, Inc.s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the Company), today issued the following open letter to the Companys Board of Directors. *** August 13, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City...

SEER Investors Have Opportunity to Join Seer, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. (Seer or the Company) (NASDAQ: SEER) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether...

Radoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc.

Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the Company), today submitted the following improved non-binding proposal to acquire the Company their fourth such proposal for $2.55 per share in cash plus a...

Radoff-JEC Group Urges Seer Stockholders to Vote FOR All Three of its Independent, Highly Qualified Nominees on the WHITE Proxy Card TODAY

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the Radoff-JEC Group or we), who collectively own approximately 7.7% of Seer, Inc.s (NASDAQ: SEER) (Seer or the Company) outstanding common stock, today issued the following statement reminding their fellow stockholders...

Radoff-JEC Group Announces That Glass Lewis Has Joined ISS in Supporting its Case for Change at Seer, Inc.

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the Radoff-JEC Group or we), who collectively own approximately 7.7% of Seer, Inc.s (NASDAQ: SEER) (Seer or the Company) outstanding common stock, today announced that independent proxy advisory firm Glass, Lewis & Co...

Radoff-JEC Group Announces ISS Support of its Case for Change at Seer, Inc.

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the Radoff-JEC Group or we), who collectively own approximately 7.7% of Seer, Inc.s (NASDAQ: SEER) (Seer or the Company) outstanding common stock, today announced that leading independent proxy advisory firm...

The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Companys Blatant Rewriting of History

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the Radoff-JEC Group or we) today issued a letter to stockholders of Seer, Inc. (NASDAQ: SEER) (Seer or the Company) ahead of the Companys July 28, 2026 Annual Meeting of Stockholders. This press release features...

• Reported GAAP EPS of -$0.25 up 21.88% YoY
• Reported revenue of $3.98M down -3.40% YoY
• Seer expects full-year 2026 revenue of $13.5M to $14.5M, compared with its prior $16M to $18M range; continued academic and government funding pressure extended sales cycles.

Seer lowered full-year revenue guidance as continued academic and government funding pressure extended sales cycles, reported third-quarter revenue down 3% year over year, and used approximately $34.5M in operating cash.

Seers Proteograph XT averaged approximately 6,060 proteins per sample with a 1.9% missing-protein-measurement rate; established and new pharmaceutical customers purchased consumables and instruments, and cash was $198.1M.

Seer, Inc. engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite consists of automation instruments and software, which provide a workflow to make proteomic profiling. The company was founded by Philip Ma, Robert S. Langer Jr. and Omid C. Farokhzad on March 16, 2017 and is headquartered in Redwood City, CA.

Seer Inc - Ordinary Shares - Class A

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.22	--	--	N/A
Q3 '26	-$0.26	-$0.25	3.85%	BEAT
Q2 '26	-$0.27	-$0.31	-14.81%	MISSED
Q1 '26	-$0.29	-$0.30	-1.69%	MISSED
Q4 '25	-$0.32	-$0.29	9.38%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

SEER Earnings

Latest Earnings Results: Q3 '26

Historical Earnings